Shopping Cart
- Remove All
Your shopping cart is currently empty
DM1-PEG4-DBCO
😃Good
Catalog No. T17832
DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for developing antibody-drug conjugates (ADCs). This conjugation aims to mitigate systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s ability as an antibody-conjugatable maytansinoid.
DM1-PEG4-DBCO
😃Good
Catalog No. T17832
DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for developing antibody-drug conjugates (ADCs). This conjugation aims to mitigate systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s ability as an antibody-conjugatable maytansinoid.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 100 mg | Inquiry | Backorder | |
| 500 mg | Inquiry | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "DM1-PEG4-DBCO"
Mc-VC-PAB-SN38
Mc-VC-PAB-SN38
T392221801838-28-7
Mc-VC-PAB-SN38 consists of a cleavable ADC linker (Mc-VC-PAB) and SN38, which is part of an antibody-coupled reactive molecule commonly used to synthesize antibody-coupled reactive molecules (ADCs) that target sites of action.
- $193
Size
QTY
Deruxtecan
T150981599440-13-7
Deruxtecan is an ADC drug-linker conjugate composed of a derivative of DX-8951 (DXd) and a maleimide-GGFG peptide linker used in the synthesis of DS-8201 and U3-1402.
- $139
Size
QTY
Val-Cit-PAB-MMAE
T18867644981-35-1
Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE . MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization[1].
- $50
Size
QTY
VCMMAE
mc-vc-PAB-MMAE
T4232646502-53-6
VCMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity.
- $30
Size
QTY
Vc-MMAD
T188701401963-17-4
Vc-MMAD, a drug-linker conjugate for Antibody-Drug Conjugates (ADCs), combines the ADC linker Val-Cit (Valine-Citrulline) with the potent tubulin inhibitor MMAD. This compound leverages the targeting capability of ADCs to deliver the cytotoxic agent MMAD specifically to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects.
- $52
Size
QTY
SMCC-DM1
DM1-SMCC
T168991228105-51-8
SMCC-DM1 is a drug-coupler coupler consisting of a potent microtubule disrupter, DM1, and a coupler, SMCC, for the preparation of antibody-drug couplers.
- $97
Size
QTY
Fmoc-Val-Cit-PAB-MMAE
T179831350456-56-2
Fmoc-Val-Cit-PAB-MMAE is consisted of the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC.
- $37
Size
QTY
Mc-MMAE
Cited
Maleimidocaproyl-monomethylauristatin E
T18312863971-24-8
Mc-MMAE (Maleimidocaproyl-monomethylauristatin E) is a drug-linker conjugate for ADC. Mc-MMAE is a maleimidocaproyl-conjugated monomethyl auristatin E, which is a potent tubulin inhibitor.
- $163
Size
QTY
CitedCL2A-SN-38
CL2A-SN38, CL2A SN 38
T177311279680-68-0
CL2A-SN-38 consists of a CL2A linker and an anticancer compound, SN-38, which delivers active molecules within tumor cells and in the tumor microenvironment, often in conjunction with antibodies to make biologically active antibody-coupled reactive molecules (ADCs).
- $147
Size
QTY
McMMAF
Maleimidocaproyl monomethylauristatin F
T16031863971-19-1
McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.It is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful agent for make antibody drug conjugate (ADC) for targeted drug delivery.
- $51
Size
QTY
Vipivotide tetraxetan
PSMA-617
T125731702967-37-0
Vipivotide tetraxetan (PSMA-617) is a highly potent inhibitor of prostate-specific membrane antigen (PSMA) with a Ki of 0.37 nM.
- $193
Size
QTY
Lys-SMCC-DM1
Lys-Nε-MCC-DM1
T119171281816-04-3
Lys-SMCC-DM1 (Lys-Nε-MCC-DM1) is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It contains the microtubule polymerization inhibitor DM1 as the active metabolite, which inhibits microtubule polymerization. It is commonly used in breast cancer research.
- $289
Size
QTY
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for developing antibody-drug conjugates (ADCs). This conjugation aims to mitigate systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s ability as an antibody-conjugatable maytansinoid. |
| Molecular Weight | 1198.79 |
| Formula | C63H80ClN5O16 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy DM1-PEG4-DBCO | purchase DM1-PEG4-DBCO | DM1-PEG4-DBCO cost | order DM1-PEG4-DBCO | DM1-PEG4-DBCO chemical structure | DM1-PEG4-DBCO formula | DM1-PEG4-DBCO molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.